| Id: | acc3148 |
| Group: | 2sens |
| Protein: | PDK4 |
| Gene Symbol: | PDK4 |
| Protein Id: | Q16654 |
| Protein Name: | PDK4_HUMAN |
| PTM: | ubiquitination |
| Site: | unclear |
| Site Sequence: | |
| Disease Category: | Immune system diseases |
| Disease: | Colitis |
| Disease Subtype: | Acute Severe Ulcerative Colitis |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | Cyclosporine A |
| Drug Info: | Cyclosporine A (CsA) is an immunosuppressive drug often used to prevent organ - rejection in transplant patients. |
| Relation: |
Cyclosporine A
➜
PDK4-unclear
DOWN
➜
Colitis
Alleviate
|
| Effect: | modulate |
| Effect Info: | "Cyclosporine inhibits the ubiquitination of PDK4 by downregulating SIRT6, enhances glycolysis, and regulates neutrophil function to alleviate ASUC." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 33634990 |
| Sentence Index: | 33634990_7-8 |
| Sentence: | "RESULTS: We found that HIF-1alpha expression and glycolysis significantly increased, while the release of IL-8, myeloperoxidase (MPO) and reactive oxygen species (ROS), the apoptosis, and ability of migration markedly decreased in neutrophils of ASUC patients who responded to CsA (Response group) compared with those who did not respond to CsA (Nonresponse group). We also observed that CsA-induced functional alternation of neutrophils was initiated through suppressing SIRT6 expression, which is responsible for expression of the downstream signaling molecules (e.g., HIF-1alpha, PFKFB3) and PDK4 ubiquitination, leading to fueling neutrophil glycolysis and TCA cycle." |
Sequence & Structure:
MKAARFVLRSAGSLNGAGLVPREVEHFSRYSPSPLSMKQLLDFGSENACERTSFAFLRQELPVRLANILKEIDILPTQLVNTSSVQLVKSWYIQSLMDLVEFHEKSPDDQKALSDFVDTLIKVRNRHHNVVPTMAQGIIEYKDACTVDPVTNQNLQYFLDRFYMNRISTRMLMNQHILIFSDSQTGNPSHIGSIDPNCDVVAVVQDAFECSRMLCDQYYLSSPELKLTQVNGKFPDQPIHIVYVPSHLHHMLFELFKNAMRATVEHQENQPSLTPIEVIVVLGKEDLTIKISDRGGGVPLRIIDRLFSYTYSTAPTPVMDNSRNAPLAGFGYGLPISRLYAKYFQGDLNLYSLSGYGTDAIIYLKALSSESIEKLPVFNKSAFKHYQMSSEADDWCIPSREPKNLAKEVAM
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 3 | Completed | lactic acidosis | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 3 | Active, not recruiting | pyruvate dehydrogenase deficiency | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 2 | Completed | head and neck squamous cell carcinoma | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 2 | Recruiting | glioblastoma multiforme | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 2 | Completed | glioblastoma multiforme | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 2 | Completed | heart disease | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 2 | Completed | lactic acidosis | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 2 | Terminated | breast cancer | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 2 | Terminated | lung cancer | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 1 | Withdrawn | glioblastoma multiforme | ClinicalTrials |
| PDK4 | SODIUM DICHLOROACETATE | Pyruvate dehydrogenase kinase inhibitor | 1 | Completed | pulmonary arterial hypertension | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
